ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$29.74 USD
+1.33 (4.68%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.73 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Income Statements
Fiscal Year end for ArriVent BioPharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 0 | 0 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 75 | 37 | 52 | 0 | 0 |
Income After Depreciation & Amortization | -75 | -37 | -52 | 0 | 0 |
Non-Operating Income | 5 | 0 | 0 | NA | NA |
Interest Expense | 0 | 0 | 0 | NA | NA |
Pretax Income | -69 | -37 | -52 | NA | NA |
Income Taxes | 0 | 0 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -69 | -37 | -52 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -69 | -37 | -52 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | -37 | -52 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | NA | NA |
Income After Depreciation & Amortization | -75 | -37 | -52 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.14 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -32.38 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -32.38 | -28.90 | NA | NA | NA |
Fiscal Year end for ArriVent BioPharma, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | NA | NA |
Cost Of Goods | NA | 0.00 | 0.00 | NA | NA |
Gross Profit | NA | 0.00 | 0.00 | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 25.70 | 20.68 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -25.70 | -20.68 | 0.00 | 0.00 |
Non-Operating Income | NA | 3.82 | 3.26 | NA | NA |
Interest Expense | NA | 0.00 | 0.00 | NA | NA |
Pretax Income | NA | -21.87 | -17.42 | NA | NA |
Income Taxes | NA | 0.00 | 0.00 | NA | NA |
Minority Interest | NA | 0.00 | 0.00 | NA | NA |
Investment Gains/Losses | NA | 0.00 | 0.00 | NA | NA |
Other Income/Charges | NA | 0.00 | 0.00 | NA | NA |
Income From Cont. Operations | NA | -21.87 | -17.42 | NA | NA |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | NA | NA |
Net Income (GAAP) | NA | -21.87 | -17.42 | NA | NA |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 33.50 | 25.05 | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | -0.65 | -0.70 | NA | NA |
Diluted Net EPS (GAAP) | NA | -0.65 | -0.70 | NA | NA |